NSECredit Rating1 Jul 2026 · 1 Jul 2026, 06:40 pm
Credit Rating
Alembic Pharmaceuticals Limited · APLLTD
✦ AI SummaryRating Change
Alembic Pharmaceuticals Limited has informed the Exchange about the reaffirmation of its credit rating on bank loan facilities and commercial paper by CRISIL Ratings Limited.
Analysis Scores
Earnings Impact0/10
Growth Catalyst0/10
Governance Concern0/10
Regulatory Risk0/10
Balance Sheet Risk0/10
Liquidity Impact0/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Alembic Pharmaceuticals Limited has informed the Exchange about Credit Rating
Attachments (1)
📄pdf
Download →
APLLTD_01072026184020_APL_Intimation_Enhanced_Amount_Rating_Crisil_S.pdf
View document text
Date: 1st July, 2026
To, To,
The Manager, The Manager,
Department of Corporate Services, Listing Department,
BSE Limited National Stock Exchange of India Ltd.
P. J. Towers, Dalal Street, ‘Exchange Plaza’, Bandra Kurla Complex,
Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051
Scrip Code:533573 NSE Symbol: APLLTD
Dear Sir/Madam,
Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015- Reaffirmation of Credit Rating on Bank Loan
Facilities (with enhanced limits) and Commercial Paper
With reference to the captioned matter, we wish to inform you that CRISIL Ratings
Limited (CRISIL), vide its letter dated 30th June 2026, has reaffirmed its Credit Rating
on Bank Loan Facilities (with enhanced limits) and Commercial Paper. The details of
the same are given below:
Rating Amount
No Instrument Rating Action
Assigned (Rs. in Crores)
Total Bank Loan Rs. 1,100
CRISIL
1. Facilities Reaffirmed (Enhanced from
AA+/Stable
(Long Term Rating) Rs. 800)
2. Commercial Paper CRISIL A1+ Reaffirmed Rs. 1,100
The rating letters received from CRISIL are attached as an Annexure.
We request you to kindly take the same on record.
Thanking you,
Yours faithfully,
For Alembic Pharmaceuticals Limited
G Krishnan
Chief Financial Officer
ALEMBIC PHARMACEUTICALS LIMITED
REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. ● TEL: (0265) 2280550, 2280880 ● FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com ● E-mail : alembic@alembic.co.in ● CIN : L24230GJ2010PLC061123
CONFIDENTIAL
RL/ALBCPSL/398117/BLR/0626/151715
June 30, 2026
Mr. Nilesh Mistry
Head - Corporate Finance & Accounts
Alembic Pharmaceuticals Limited
Alembic Road
Vadodara
Vadodara - 390003
9925034677
Dear Mr. Nilesh Mistry,
Re: Review of Crisil Ratings on the bank facilities of Alembic Pharmaceuticals Limited
All ratings assigned by Crisil Ratings are kept under continuous surveillance and review.
Please find in the table below the ratings outstanding for the debt instruments/facilities of the company, and the rating
actions by Crisil Ratings on the ratings as on date.
Total Bank Loan Facilities Rated Rs.1100 Crore (Enhanced from Rs.800 Crore)
Long Term Rating Crisil AA+/Stable (Reaffirmed)
(Bank-wise details as per Annexure 1)
As per our Rating Agreement, Crisil Ratings would disseminate the ratings, along with the outlook, through its
publications and other media, and keep the ratings, along with the outlook, under surveillance over the life of the
instrument/facility. Crisil Ratings reserves the right to withdraw, or revise the ratings, along with the outlook, at any time,
on the basis of new information, or unavailability of information, or other circumstances which Crisil Ratings believes
may have an impact on the ratings. Please visit www.crisilratings.com and search with the name of the rated entity to
access the latest rating/s.
In the event of the company not availing the proposed facilities within a period of 180 days from the date of this letter, a
fresh letter of revalidation from Crisil Ratings will be necessary.
Crisil Ratings products / activities or ratings of instruments other than securities that are listed or proposed to be listed may
fall under the purview of financial sector regulators (FSRs) other than SEBI. In respect of such products / activities or
ratings (under the purview of other FSRs such as Reserve Bank of India (RBI), Ministry of Corporate Affairs (MCA),
Insurance Regulatory and Development Authority of India (IRDAI), among others), the grievance / dispute redressal and
investor protection mechanisms available under SEBI regulations shall not be applicable. A list of products/activities or
ratings of instruments falling under the purview of various FSRs along with the names of respective FSRs has been duly
disclosed by Crisil Ratings on its website.
A link to the same has been provided below for ready reference:
https://www.crisilratings.com/en/home/our-business/ratings/regulatory-disclosures/list-of-activities-instruments-and-
names-of-regulators.html
Should you require any clarification, please feel free to get in touch with us.
With warm regards,
Yours sincerely,
Aditya Jhaver Nivedita Shibu
Disclaimer: A rating by Crisil Ratings reflects Crisil Ratings’ current opinion on the likelihood of timely payment of the obligations under the rated instrument, and does
not constitute an audit of the rated entity by Crisil Ratings. Our ratings are based on information provided by the issuer or obtained by Crisil Ratings from sources it
considers reliable. Crisil Ratings does not guarantee the completeness or accuracy of the information on which the rating is based. A rating by Crisil Ratings is not a
recommendation to buy / sell or hold the rated instrument; it does not comment on the market price or suitability for a particular investor. Crisil Ratings has a practice of
keeping all its ratings under surveillance and ratings are revised as and when circumstances so warrant. Crisil Ratings is not responsible for any errors and especially
states that it has no financial liability whatsoever to the subscribers / users / transmitters / distributors of its ratings. Crisil Ratings’ criteria are available without charge to
the public on the web site, www.crisilratings.com. Crisil Ratings or its associates may have other commercial transactions with the company/entity. For the latest rating
information on any instrument of any company rated by Crisil Ratings, please visit www.crisilratings.com or contact Customer Service Helpdesk at
Crisilratingdesk@crisil.com or at 1800-267-3850
Director - Crisil Ratings Director - Crisil Ratings
Annexure 1 - Bank-wise details of various facility classes (outstanding facilities)
Amount (Rs.
S.No. Bank Facility Bank Outstanding Rating
in Crore)
Cash Credit & Working
1 HDFC Bank Limited 200 Crisil AA+/Stable
Capital Demand Loan
Cash Credit & Working Kotak Mahindra Bank
2 100 Crisil AA+/Stable
Capital Demand Loan Limited
Cash Credit & Working The Hongkong and Shanghai
3 100 Crisil AA+/Stable
Capital Demand Loan Banking Corporation Limited
Cash Credit & Working
4 Citibank N. A. 100 Crisil AA+/Stable
Capital Demand Loan
Cash Credit & Working
5 Axis Bank Limited 100 Crisil AA+/Stable
Capital Demand Loan
Working Capital Demand
6 State Bank of India 100 Crisil AA+/Stable
Loan
Working Capital Demand
7 RBL Bank Limited 200 Crisil AA+/Stable
Loan
Working Capital Demand
8 State Bank of India 200 Crisil AA+/Stable
Loan
Total 1100
1-5. 100% interchangeability between funded and non-funded
Disclaimer: A rating by Crisil Ratings reflects Crisil Ratings’ current opinion on the likelihood of timely payment of the obligations under the rated instrument, and does
not constitute an audit of the rated entity by Crisil Ratings. Our ratings are based on information provided by the issuer or obtained by Crisil Ratings from sources it
considers reliable. Crisil Ratings does not guarantee the completeness or accuracy of the information on which the rating is based. A rating by Crisil Ratings is not a
recommendation to buy / sell or hold the rated instrument; it does not comment on the market price or suitability for a particular investor. Crisil Ratings has a practice of
keeping all its ratings under surveillance and ratings are revised as and when circumstances so warrant. Crisil Ratings is not responsible for any errors and especially
states that it has no financial liability whatsoever to the subscribers / users / transmitters / distributors of its ratings. Crisil Ratings’ criteria are available without charge to
the public on the web site, www.crisilratings.com. Crisil Ratings or its associates may have other commercial transactions with the company/entity. For the latest rating
information on any instrument of any company rated by Crisil Ratings, please visit www.crisilratings.com or contact Customer Service Helpdesk at
Crisilratingdesk@crisil.com or at 1800-267-3850
Annexure: List of instruments and names of regulators of the instr
[Showing first 8,000 characters — download PDF for full document]